Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.55 |
| ▸ | HRH1 | P35367 | 3/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.46 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.46 |
| ▸ | DRD1 | P21728 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.46 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 2/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10653002 | 0.89 | HRH3 (0.57) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL29901385 | 0.89 | HRH3 (0.57) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL10652720 | 0.87 | HRH3 (0.51) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| Hydrochloric Acid SCHEMBL30516224 | 0.87 | HRH3 (0.55) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL12120297 | 0.85 | CYP2D6 (0.45) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| Trifluoroacetic Acid SCHEMBL838129 | 0.85 | PPARG (0.46) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL4445537 | 0.82 | CYP2D6 (0.72) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL434743 | 0.82 | CYP2D6 (0.56) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL1904189 | 0.81 | CYP2D6 (0.55) | CYP2D6CYP2C19HRH1CHRM2ADRA2A | |
| SCHEMBL31490354 | 0.81 | POLB (0.58) | CYP2D6CYP2C19HRH1CHRM2ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112876688-B | Preparation method of nano micelle suitable for tandem catalysis | 浙江理工大学 | 2022-10-28 | — | — | CN | claimed |
| CN-1030319-C | 20- and 21-amino steroid | EUPJOHN CORP (US) | 1995-11-22 | — | — | CN | claimed |
| CN-86106226-A | 20-and 21-amino steroids | — | 1987-03-18 | — | — | CN | claimed |
| CN-111943930-B | Synthesis process of Lasmidinan | 南京三元阳普医药科技有限公司 | 2022-11-01 | — | — | CN | disclosed |
| CN-112876688-B | Preparation method of nano micelle suitable for tandem catalysis | 浙江理工大学 | 2022-10-28 | — | — | CN | disclosed |
| US-20220331275-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | PHILERA NEW ZEALAND LTD. (NZ) | 2022-10-20 | — | — | US | disclosed |
| EP-3982943-A1 | COMBINATION TREATMENTS FOR CENTRAL NERVOUS SYSTEM DISORDERS | Philera New Zealand Ltd. (NZ) | 2022-04-20 | — | — | EP | disclosed |
| CN-111943930-A | Synthesis process of Lasmidinan | 南京三元阳普医药科技有限公司 | 2020-11-17 | — | — | CN | disclosed |
| EP-2013182-B1 | AMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2013-09-04 | — | — | EP | disclosed |
| EP-2383271-B1 | Aminoquinolones as GSK-3 Inhibitors | KYORIN SEIYAKU KK (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-8143251-B2 | Triazolotriazines as kinase inhibitors | INCYTE CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| WO-2008021781-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| CN-1030319-C | 20- and 21-amino steroid | EUPJOHN CORP (US) | 1995-11-22 | — | — | CN | disclosed |
| EP-0113572-B1 | PYRIDINE DERIVATIVES | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1988-02-03 | — | — | EP | disclosed |
| CN-86106226-A | 20-and 21-amino steroids | — | 1987-03-18 | — | — | CN | disclosed |
| US-4547506-A | 2-Pyridylaminoakylamino-4-pyrimidones useful as histamine H1 -antagonists | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1985-10-15 | — | — | US | disclosed |
| EP-0113572-A2 | Pyridine derivatives | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1984-07-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039457-A1 | TRIAZOLOTRIAZINES AS KINASE INHIBITORS | MET, ERBB2, RET | CYP2D6 2893/4885CYP2C19 1670/4885HRH1 2050/4885 |
| US-20070254866-A1 | Aminoquinolones as GSK-3 inhibitors | GSK3B, GSK3A, GSKIP | CYP2D6 2378/4885CYP2C19 3526/4885HRH1 3735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.